Pradip Arvind, Steel Daniella, Jacobsson Susanna, Holmgren Gustav, Ingelman-Sundberg Magnus, Sartipy Peter, Björquist Petter, Johansson Inger, Edsbagge Josefina
Takara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden; Novo Nordisk A/S, Stem Cell Development, 2880 Bagsværd, Denmark.
Takara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden; Horizon Discovery Ltd, 7100 Cambridge Research Park, Waterbeach, Cambridge CB25 9TL, UK.
Stem Cells Int. 2016;2016:2475631. doi: 10.1155/2016/2475631. Epub 2016 Jan 5.
Hepatotoxicity is one of the most cited reasons for withdrawal of approved drugs from the market. The use of nonclinically relevant in vitro and in vivo testing systems contributes to the high attrition rates. Recent advances in differentiating human induced pluripotent stem cells (hiPSCs) into pure cultures of hepatocyte-like cells expressing functional drug metabolizing enzymes open up possibilities for novel, more relevant human cell based toxicity models. The present study aimed to investigate the use of hiPSC derived hepatocytes for conducting mechanistic toxicity testing by image based high content analysis (HCA). The hiPSC derived hepatocytes were exposed to drugs known to cause hepatotoxicity through steatosis and phospholipidosis, measuring several endpoints representing different mechanisms involved in drug induced hepatotoxicity. The hiPSC derived hepatocytes were benchmarked to the HepG2 cell line and generated robust HCA data with low imprecision between plates and batches. The different parameters measured were detected at subcytotoxic concentrations and the order of which the compounds were categorized (as severe, moderate, mild, or nontoxic) based on the degree of injury at isomolar concentration corresponded to previously published data. Taken together, the present study shows how hiPSC derived hepatocytes can be used as a platform for screening drug induced hepatotoxicity by HCA.
肝毒性是已批准药物从市场上撤市的最常见原因之一。使用非临床相关的体外和体内测试系统导致了高淘汰率。将人诱导多能干细胞(hiPSC)分化为表达功能性药物代谢酶的纯肝细胞样细胞培养物的最新进展为新型、更相关的基于人类细胞的毒性模型开辟了可能性。本研究旨在通过基于图像的高内涵分析(HCA)研究hiPSC来源的肝细胞在进行机制性毒性测试中的应用。将hiPSC来源的肝细胞暴露于已知通过脂肪变性和磷脂沉积导致肝毒性的药物中,测量代表药物诱导肝毒性所涉及不同机制的几个终点。将hiPSC来源的肝细胞与HepG2细胞系进行基准比较,并生成了稳健的HCA数据,板间和批次间的不精确性较低。在亚细胞毒性浓度下检测到所测量的不同参数,并且根据等摩尔浓度下的损伤程度对化合物进行分类(分为严重、中度、轻度或无毒)的顺序与先前发表的数据一致。综上所述,本研究展示了hiPSC来源的肝细胞如何用作通过HCA筛选药物诱导肝毒性的平台。